All Stories

  1. One-Year Progression of Speech, Drooling and Swallowing in Parkinson's Disease

    Article • American Journal of Speech-Language Pathology, June 2026, American Speech-Language-Hearing Association (ASHA)

    Professor Tiago F Outeiro, Joaquim Ferreira, Isabel Peixoto Guimarães, David Nascimento

  2. Do Acoustic Characteristics of Dysarthria in People With Parkinson's Disease Differ Across Languages?

    Article • Journal of Speech Language and Hearing Research, May 2024, American Speech-Language-Hearing Association (ASHA)

    Professor Rui Rothe-Neves, Cyril Atkinson-Clement, Joaquim Ferreira, Isabel Peixoto Guimarães

  3. Co-designing Customizable Clinical Dashboards with Multidisciplinary Teams: Bridging the Gap in Chronic Disease Care

    Article • May 2024, ACM (Association for Computing Machinery)

    Joaquim Ferreira, Tiago Guerreiro

  4. The Efficacy and Safety of Physiotherapy in People with Dementia: A Systematic Review

    Article • Journal of Alzheimer’s Disease, August 2023, IOS Press

    Joaquim Ferreira

  5. Assessment Tools to Evaluate Motor Function in People with Dementia: A Systematic Review

    Article • Journal of Alzheimer’s Disease, August 2022, IOS Press

    Joaquim Ferreira

  6. Are Happiness and Well-being the Same Outcome?

    Article • Journal of Parkinson’s Disease, October 2020, IOS Press

    Joaquim Ferreira

  7. Gait Kinematic Parameters in Parkinson’s Disease: A Systematic Review

    Article • Journal of Parkinson’s Disease, May 2020, IOS Press

    Joaquim Ferreira

  8. Physician perception versus true efficacy of tetrabenazine for Huntington’s disease

    Article • Current Medical Research and Opinion, July 2018, Taylor & Francis

    Dr Filipe B Rodrigues, Joaquim Ferreira

  9. Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study

    Article • Expert Opinion on Drug Safety, February 2018, Taylor & Francis

    Professor Daniel Caldeira, Joaquim Ferreira

  10. What is Functional Mobility Applied to Parkinson’s Disease?

    Article • Journal of Parkinson’s Disease, February 2018, IOS Press

    Joaquim Ferreira

  11. The launch of opicapone for Parkinson’s disease: negatives versus positives

    Article • Expert Opinion on Drug Safety, February 2018, Taylor & Francis

    Joaquim Ferreira

  12. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson’s Disease

    Article • Journal of Parkinson’s Disease, August 2017, IOS Press

    Joaquim Ferreira

  13. Fifteen Years of Clinical Trials in Huntington’s Disease: A Very Low Clinical Drug Development Success Rate

    Article • Journal of Huntington s Disease, June 2017, IOS Press

    Joaquim Ferreira

  14. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA

    Article • Expert Review of Neurotherapeutics, June 2017, Taylor & Francis

    Professor Heinz Reichmann, Joaquim Ferreira, Andrew Lees